Oral versus transdermal selegiline: Antidepressant-like activity in rats

Pharmacology Biochemistry and Behavior

Volumn 63, Issue 3, 1999, Pages 501-506

  Gordon, Marcia N ^a   Muller, Christopher D ^a   Sherman, Kathleen A ^a   Morgan, David G ^a   Azzaro, Albert J ^b   Wecker, Lynn ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Somerset Pharmaceuticals   (United States)

Author keywords

Antidepressant like activity; Forced swim test; l deprenyl; Monoamine oxidases; Selegiline; Transdermal drug administration

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; SELEGILINE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; ENZYME ACTIVITY; FORCED SWIMMING TEST; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; ISOENZYMES; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; RATS; RATS, INBRED F344; SELEGILINE; SWIMMING;

EID: 0033061532     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00016-7     Document Type: Article

References (30)

1. Azzaro A.J., King J., Kotzuk J., Schoepp D.D., Frost J., Schochet S. Guinea pig striatum as a model of human dopamine deamination. The role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism J. Neurochem. 45:1985;949-956.
2. Barrett J.S., Hochadel T.J., Morales R.J., Rohatagi S., DeWitt K.E., Watson S.K., DiSanto A.R. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. Am. J. Ther. 3:1996;688-698.
3. Berry M.D., Juorio A.V., Paterson I.A. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog. Neurobiol. 44:1994;141-161.
4. Braestrup C., Andersen H., Randrup A. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur. J. Pharmacol. 34:1975;181-187.
5. Cabib S., Zocchi A., Puglisi-Allegra S. A comparison of the behavioral effects of minaprine, amphetamine and stress. Psychopharmacology (Berlin). 121:1995;73-80.
6. Dourish C.T. A pharmacological analysis of the hyperactivity syndrome induced by beta-phenylethylamine in the mouse. Br. J. Pharmacol. 77:1982;129-139.
7. Engberg G., Elebring T., Nissbrandt H. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; Effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J. Pharmacol. Exp. Ther. 259:1991;841-847.
8. Fozard J.R., Zreika M., Robin M., Palfreyman M.G. The functional consequences of inhibition of monoamine oxidase type B. Comparison of the pharmacological properties of L-deprenyl and MDL 72145 Naunyn Schmiedebergs Arch. Pharmacol. 331:1985;186-193.
9. Gelowitz D.L., Richardson J.S., Wishart T.B., Yu P.H., Lai C.-T. Chronic L-deprenyl or L-amphetamine. Equal cognitive enhancement, unequal MAO inhibition Pharmacol. Biochem. Behav. 47:1994;41-45.
10. Head E., Milgram N.W. Changes in spontaneous behavior in the dog following oral administration of L-deprenyl. Pharmacol. Biochem. Behav. 43:1992;749-757.
11. Heinonen E.H., Anttila M.I., Lammintausta R.A.S. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther. 56:1994;742-749.
12. Heinonen E.H., Myllyla V., Sotaniemi K., Lammintausta R., Salonen J.S., Anttila M., Savijarvi M., Kotila M., Rinne U.K. Pharmacokinetics and metabolism of selegiline. Acta Neurol. Scand. 126:1989;93-99.
13. Karoum F., Chuang L.W., Eisler T., Calne D.B., Liebowitz M.R., Quitkin F.M., Klein D.F., Wyatt R.J. Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit. A biochemical assessment Neurology. 32:1982;503-509.
14. Kuhn W., Muller T. The clinical potential of Deprenyl in neurologic and psychiatric disorders. J. Neural Transm. 48:1996;85-93.
15. Laux G. Do MAO-B inhibitors have any role in the treatment of depression. Szelenyi I. Inhibitors of monoamine oxidase B. 1993;319-326 Birkhauser Verlag, Basel, Switzerland.
16. Mann J.J., Aarons S.F., Wilner P.J., Keilp J.G., Sweeney J.A., Pearlstein T., Frances A.J., Kocsis J.H., Brown R.P. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. Arch. Gen. Psychiatry. 46:1989;45-50.
17. Mann J.J., Frances A., Kaplan R.D., Kocsis J., Peselow E.D., Gershon S. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. J. Clin. Psychopharmacol. 2:1982;54-57.
18. Mann J.J., Frances A., Peselow E.D., Gershon S. Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendogenous depression. Psychopharmacol. Bull. 18:1982;182-184.
19. Mann J.J., Gershon S. L-Deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci. 26:1980;877-882.
20. Mendlewicz J., Youdim M.B.H. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression. A double blind evaluation Br. J. Psychiatry. 142:1983;508-511.
21. Okuda C., Segal D.S., Kuczenski R. Deprenyl alters behavior and caudate dopamine through an amphetamine-like action. Pharmacol. Biochem. Behav. 43:1992;1075-1080.
22. Paterson I.A., Juorio A.V., Boulton A.A. 2-Phenylethylamine. A modulator of catecholamine transmission in the mammalian central nervous system? J. Neurochem. 55:1990;1827-1837.
23. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats. A new model sensitive to antidepressant treatments Eur. J. Pharmacol. 47:1978;379-391.
24. Reynolds G.P., Riederer P., Sandler M., Jellinger K., Seemann D. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J. Neural Transm. 43:1978;271-277.
25. Rohatagi R., Barrett J.S., DeWitt K.E., Morales R.J. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharmacol. Drug Disp. 18:1997;567-584.
26. Sortwell C.E., Sagen J. Induction of antidepressive activity by monoaminergic transplants in rat neocortex. Pharmacol. Biochem. Behav. 46:1993;225-230.
27. Thase M.E., Trivedi M.H., Rush A.J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology (Berlin). 12:1995;185-219.
28. Yang H.Y., Neff N.H. The monoamine oxidases of brain. Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines J. Pharmacol. Exp. Ther. 189:1974;733-740.
29. Yasar S., Bergman J. Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies. Clin. Pharmacol. Ther. 56:1994;768-773.
30. Yu P.H. Pharmacological and clinical implications of MAO-B inhibitors. Gen. Pharmacol. 25:1994;1527-1539.